Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1477690 | 0.80 | GRM5 (0.43) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL23851284 | 0.77 | GRM5 (0.36) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL19781334 | 0.75 | RAPGEF4 (0.33) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL19748358 | 0.75 | KDM1A (0.33) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL5993333 | 0.75 | ALDH1A1 (0.42) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL31280972 | 0.74 | GRM5 (0.41) | GRM5 | |
| SCHEMBL483771 | 0.74 | MAP2K1 (0.44) | APPGABRA1GABRA5GABRA3GABRA2 | |
| SCHEMBL9232027 | 0.74 | MAP2K1 (0.42) | — | |
| SCHEMBL4683351 | 0.74 | RAB9A (0.42) | — | |
| SCHEMBL28577877 | 0.73 | GABRA1 (0.44) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411057-B1 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | LILLY CO ELI (US) | 2020-05-06 | — | — | EP | disclosed |
| EP-2550255-B1 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | LILLY CO ELI (US) | 2016-04-27 | — | — | EP | disclosed |
| US-20130302248-A1 | Imaging Agents for Detecting Neurological Disorders | LILLY CO ELI (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130302248-A1 | Imaging Agents for Detecting Neurological Disorders | LILLY CO ELI (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130302248-A1 | Imaging Agents for Detecting Neurological Disorders | LILLY CO ELI (US) | 2013-11-14 | — | — | US | disclosed |
| US-8491869-B2 | Imaging agents for detecting neurological disorders | ELI LILLY AND COMPANY (US) | 2013-07-23 | — | — | US | disclosed |
| US-8491869-B2 | Imaging agents for detecting neurological disorders | ELI LILLY AND COMPANY (US) | 2013-07-23 | — | — | US | disclosed |
| EP-2411057-A2 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | Siemens Medical Solutions USA, Inc. (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20110182812-A1 | Imaging Agents for Detecting Neurological Disorders | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110182812-A1 | Imaging Agents for Detecting Neurological Disorders | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| WO-2010111303-A2 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| US-20100239496-A1 | Imaging agents for detecting neurological disorders | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100239496-A1 | Imaging agents for detecting neurological disorders | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130302248-A1 | Imaging Agents for Detecting Neurological Disorders | MAPT, APP, PSEN1 | APP 2/4885GABRA1 1102/4885GABRG2 1452/4885 |
| US-20110182812-A1 | Imaging Agents for Detecting Neurological Disorders | MAPT, APP, PSEN1 | APP 2/4885GABRA1 1183/4885GABRG2 1286/4885 |
| US-20100239496-A1 | Imaging agents for detecting neurological disorders | MAPT, APP, PSEN1 | APP 2/4885GABRA1 1102/4885GABRG2 1452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.